N1VO34:BVMF
Նովո Նորդիսկ
24,34 R$
0,00%
(0,00) 1D
2 հոկ, 16:56:00 GMT-3 · BRL
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for N1VO34...
Open
24,80 R$
High
24,80 R$
Low
24,26 R$
Mkt. cap
128,18 մլրդ
Avg. vol.
31,15 հզր
Volume
6,35 հզր
52-wk high
42,43 R$
52-wk low
22,90 R$
Shares outstanding
3,39 մլրդ
No. of employees
67 հզր
Open
24,80 R$
High
24,80 R$
Low
24,26 R$
Mkt. cap
128,18 մլրդ
Avg. vol.
31,15 հզր
Volume
6,35 հզր
52-wk high
42,43 R$
52-wk low
22,90 R$
Shares outstanding
3,39 մլրդ
No. of employees
67 հզր
News stories
From web sources and news partners
Yahoo Finance
·
5 ժամ առաջ
Novo Nordisk Holds Its 2026 Outlook As FDA Review Of Its Blood Disorder Drug Runs Long
The Motley Fool
·
12 ժամ առաջ
Novo Nordisk vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
TipRanks
·
13 ժամ առաջ
Novo Nordisk Tests Zenagamtide Dosing to Sharpen Its Obesity Drug Pipeline
Simply Wall Street
·
1 օր առաջ
Novo Nordisk (NVO) Stock Looks Reasonable Given Uncertain Long Term Earnings
Profile
Novo is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily diabetes and obesity medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s.
Novo employs approximately 68,800 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds approximately 28.1% of its shares and a majority of its voting shares.
Novo is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten.
Novo is the largest pharmaceutical company in Denmark. In 2023, Novo's market capitalization exceeded the GDP of Denmark's domestic economy, and it became the highest valued company in Europe. Wikipedia
About Նովո Նորդիսկ
CEOMaziar Mike Doustdar
Employees66,7 հզր
Founded21 դեկ, 1923 թ.
HeadquartersBagsværd, Մայրաքաղաքային տարածաշրջան, Դանիա
Sector-
Websitenovonordisk.com